ESPR Files New Drug Submissions for Nexletol & Nexlizet in Canada

Published on 4 Dec 2024 on Zacks · via Yahoo Finance

Esperion files new drug submissions in Canada for Nexletol and Nexlizet as a treatment for reducing...

Read the rest of the article

Start tracking your investments with Statfolio

The FDA approves Mesoblast's Ryoncil (remestemcel-L) for treating pediatric patients with...

Zacks · via Yahoo Finance 19 Dec 2024

Krystal Biotech posts initial clinical updates on its two pipeline candidates, KB407 and KB408,...

Zacks · via Yahoo Finance 14 Dec 2024

Sanofi SNY announced that the FDA has granted a Breakthrough Therapy designation to its...

Zacks · via Yahoo Finance 13 Dec 2024

Some better-ranked stocks from the biotech sector are Immunocore Holdings plc IMCR, Spero...

Zacks · via Yahoo Finance 9 Dec 2024

Some better-ranked stocks from the biotech sector are Immunocore Holdings plc IMCR, Spero...

Zacks · via Yahoo Finance 6 Dec 2024

Some other top-ranked stocks from the biotech sector are Immunocore Holdings plc IMCR, Spero...

Zacks · via Yahoo Finance 4 Dec 2024

Esperion files new drug submissions in Canada for Nexletol and Nexlizet as a treatment for reduci...

Zacks · via Yahoo Finance 4 Dec 2024

Free Report) announced that it has filed new drug submissions (NDSs) in Canada to seek approval f...

Zacks 2 Dec 2024

MIRM's lead drug, Livmarli, is driving revenues and the momentum is likely to continue. The...

Zacks · via Yahoo Finance 29 Nov 2024

Some better-ranked stocks from the biotech sector are Immunocore Holdings plc IMCR, Spero...

Zacks · via Yahoo Finance 29 Nov 2024